Manufacturer first half profit briefs – stories you might have missed
CSL profit dips on Covid disruptions Disruptions to the collection of blood plasma have impacted biotechnology giant CSL in the first half FY22, with EBITDA operating profits down eight per cent to $3.4 billion on sales up three per cent to $8.05 billion. CEO Paul Perreault said the company had responded with multiple initiatives in…